Moffitt Cancer Center Chief Participates In Clinical Trial Resulting In FDA Approval Of New Label For Myelodysplastic Therapy VIDAZA

The Moffitt Cancer Center announced that Dr. Alan List, Physician-in-Chief, was one of the key investigators in a VIDAZA (azacitidine) clinical trial (AZA-001) whose results the U.S. Food & Drug Administration (FDA) has approved to add to the drug’s label. In May 2004, VIDAZA was the first drug approved by the FDA for the treatment of MDS. The AZA-001 study is the largest ever phase III; multi-center randomized trial involving higher-risk MDS patients.

More: continued here

Filed under: Blood on September 8th, 2008